<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467125</url>
  </required_header>
  <id_info>
    <org_study_id>1288589-4</org_study_id>
    <nct_id>NCT04467125</nct_id>
  </id_info>
  <brief_title>Nexplanon Removal: Subcutaneous vs. Topical Lidocaine</brief_title>
  <official_title>Nexplanon Removal: Subcutaneous vs. Topical Lidocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized trial of using EMLA cream for anesthesia to remove Nexplanon versus the standard
      route of subcutaneous lidocaine for anesthesia. Primary endpoints are pain during procedure
      and time to removal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain of procedure</measure>
    <time_frame>during procedure</time_frame>
    <description>Using the pain scale the participant is asked to circle the numerical value of pain they had during removal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to perform procedure</measure>
    <time_frame>procedure</time_frame>
    <description>the medical assistant times the procedure from incision to removal of the device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>How likely to recommend their anesthetic?</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider's sense of ease of removal?</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>EMLA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eutectic Lidocaine Prilocaine</intervention_name>
    <description>Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.</description>
    <arm_group_label>EMLA</arm_group_label>
    <other_name>EMLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Lidocaine</intervention_name>
    <description>Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.</description>
    <arm_group_label>Subcutaneous Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females with Nexplanon implant in place, desiring removal No allergy to lidocaine or
             any component of EMLA cream Age greater than or equal to 18years English as primary
             language Not pregnant

        Exclusion Criteria:

          -  pregnant non-emglish speaking age less than 18 yo Allergy to lidocaine or EMLA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manish Jain, MD</last_name>
    <phone>706-721-2542</phone>
    <email>majain@augusta.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augusta University Ob/Gyn Resident Continuity Clinic</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Jain, MD</last_name>
      <phone>706-721-2542</phone>
      <email>majain@augusta.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Manish Jain</investigator_full_name>
    <investigator_title>Associate Professor, Dept. of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Lidocaine, Prilocaine Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

